Date(s) - 25 Oct 2023
8:00 AM - 9:00 AM
Register to attend a free webinar to assess co-developing an NCI technology. Attendees will learn about new antibodies developed at the National Cancer Institute in the laboratory of David Fitzgerald, Ph.D. These antibodies bind a particular structure on the external domain of epidermal growth factor receptor (EGFR) which is displayed on cancer cells that express high EGFR levels or the variant termed ‘EGFRvIII.’ Importantly, these antibodies do not bind normal cells and therefore are used to deliver toxic payloads (as antibody-drug conjugates – ADCs) to cancer cells without killing normal cells. In addition, these antibodies are superior to currently approved drugs that target this receptor, including ligand-blocking monoclonal antibodies and small molecular weight kinase inhibitors. The webinar will highlight how tumors expressing high levels of human EGFR experience a significant reduction in size after treatment with several distinct ADCs made in Dr. Fitzgerald’s Lab. This invention was featured at the 2023 Technology Showcase.
When: Wednesday, October 25th. 11am-12pm ET
David Fitzgerald, Ph.D.
Laboratory of Molecular Biology
Center for Cancer Research (CCR)
National Cancer Institute
The presentation will follow a logical sequence of how anti-EGFR antibodies are generated and modified to make them cytotoxic for tumor cells with high levels of EGFR or the variant EGFRvIII. It will specifically focus on beginning with a key mouse monoclonal antibody termed ‘40H3’ and then the transition to the humanization of this antibody to produce the antibody termed ‘A10.’ These anti-EGFR antibodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptors (CARs). Attendees will have an opportunity to ask questions.
Dr. Fitzgerald and his team established that using one of the antibodies (40H3) as an antibody-drug conjugate has potential use as a potent therapeutic because of its ability to kill both breast cancer cells and epidermoid cancer cells and reduce tumor growth in mice. The 40H3 antibody is also able to bind to EGFR when overexpressed in cancers of various tissue origins and thus has broad therapeutic potential for a wide cancer patient population. Further, the 40H3 antibody has been humanized producing an antibody termed ‘A10’ which retains the full binding activity of 40H3.
Who Should Attend?